Company Overview of CSL Behring LLC
CSL Behring LLC develops, manufactures, and markets protein-based therapies for the treatment of serious and rare conditions worldwide. It offers bleeding disorders, fluid replacement, hereditary angioedema, immunoglobulin, pulmonary, and wound healing biotherapies/plasma-derived and recombinant therapies. The company also operates a plasma collection network. CSL Behring LLC was formerly known as ZLB Behring LLC and changed its name to CSL Behring LLC in 2007. The company was founded in 2000 and is based in King of Prussia, Pennsylvania. It has research and development, and manufacturing locations in the United States, Germany, Australia, and Switzerland; and regional sales offices in Argen...
1020 First Avenue
P.O. Box 61501
King of Prussia, PA 19406-0901
Founded in 2000
Key Executives for CSL Behring LLC
Chief Executive Officer and Managing Director
Chief Executive Officer of CSL
Chief Scientific Officer and R&D Director
Executive Vice President of Legal and General Counsel
Compensation as of Fiscal Year 2013.
CSL Behring LLC Key Developments
CSL Behring Announces phase III Study Updates
Feb 20 14
CSL Behring announced it has enrolled the first patient in COMPACT, an international phase III study of a volume-reduced, subcutaneous formulation of C1-esterase inhibitor (C1-INH) concentrate in patients with frequent hereditary angioedema (HAE) attacks (NCT01912456). This phase of the COMPACT program will assess the efficacy and safety of a new formulation of the CSL Behring C1-INH concentrate in preventing hereditary angioedema attacks when the therapy is administered twice weekly under the skin of patients diagnosed with HAE. The COMPACT phase III, double-blind, randomized, placebo-controlled, cross-over study enrolls adolescent and adult patients with HAE types I or II who have frequent attacks. The study will measure the number of hereditary angioedema attacks that subjects experience while receiving each treatment. Subjects will be able to take on-demand medication for acute attacks at any time during the study.
Kcentra(R), from CSL Behring, Receives FDA Approval for Use in Warfarin Reversal in Patients Undergoing Surgery
Dec 13 13
CSL Behring announced that Kcentra(R) (Prothrombin Complex Concentrate [Human]) has received U.S. Food and Drug Administration (FDA) approval for an expanded indication -- urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients needing an urgent surgery or other invasive procedure. Kcentra, approved by the FDA in April 2013 for the urgent reversal of warfarin therapy in adult patients with acute major bleeding, is the only non-activated 4-factor prothrombin complex concentrate (4F-PCC) indicated in the U.S. for these uses. Kcentra helps restore blood coagulation by replenishing the levels of clotting factors that were depleted by warfarin therapy. Kcentra contains four vitamin K-dependent factors: Factor II (prothrombin), Factor VII, Factor IX and Factor X, as well as antithrombotic Proteins C and S.
CSL Behring Launches Innovative Test Kit Designed to Improve Diagnosis of Alpha-1
Nov 25 13
CSL Behring LLC announced the availability of DNA Advanced Alpha-1 Screening(TM) (DNA), a new test that aims to improve diagnosis of Alpha-1 Antitrypsin Deficiency (Alpha-1). Launched during Alpha-1 Awareness Month, DNA is the only comprehensive Alpha-1 test available that identifies known and unknown clinically relevant genetic variants to help physicians achieve an accurate diagnosis. Alpha-1 is a serious hereditary condition that can cause lung disease and/or liver disease. It is often misdiagnosed as COPD, asthma or emphysema because the symptoms are similar: shortness of breath, chronic cough, difficulty breathing, and wheezing. On average, people with Alpha-1 will see three doctors over seven years before they are accurately diagnosed. During that time, lung damage progresses. The American Thoracic Society and European Respiratory Society recommend screening adults with COPD, emphysema, or irreversible asthma for Alpha-1--associated emphysema. DNA Advanced Alpha-1 Screening was developed by Biocerna LLC and laboratory testing of the kits is provided by the company. DNA offers test results for the following: Clinical chemistry -- Blood spot assay to test patient alpha-1 antitrypsin (AAT) levels, as well as a C-reactive protein (CRP) test to provide full clinical analysis; Targeted genotyping -- Identifies all known, clinically relevant variants, including S, Z, and F; Next generation sequencing -- Sequencing of the SERPINA1 gene to identify unknown variants; Isoelectric focus -- Results compared to genetic results as a confirmatory step.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|